JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2006, 55(4):168-174

Protective Effects of the Flavonoids Osajin and Pomiferin on Heart Ischemia - Reperfusion

J. Nečas1, L. Bartošíková1, T. Florian1, J. Klusáková3, V. Suchý2, E. M. B. Naggar1, E. Janoštíková1, T. Bartošík4, M. Lišková2
1 Veterinární a farmaceutická univerzita Brno, Farmaceutická fakulta, Ústav humánní farmakologie a toxikologie
2 Veterinární a farmaceutická univerzita Brno, Farmaceutická fakulta, Ústav přírodních léčiv
3 Masarykova univerzita Brno, Lékařská fakulta, I. patologicko-anatomický ústav
4 Úrazová nemocnice, Brno

The study was undertaken to evaluate the cardioprotective potential of the flavonoids osajin and pomiferin against ischemia-reperfusion induced injury in rat hearts as a model of antioxidant-based composite therapy. Studies were performed with isolated, modified Langendorff-perfused rat hearts and ischemia of the heart was initiated by stopping the coronary flow for 30 min followed by 60 min of reperfusion (14 ml.min-1). Wistar rats were divided into four groups. The treated groups received osajin or pomiferin (5 mg/kg/day in 0.5% Avicel), the placebo group received only 0.5 Avicel; the intact group was left without any applications. Biochemical indicators of oxidative damage - malondialdehyde, superoxide dismutase, glutathione peroxidase, total antioxidant activity in serum and the myocardium have been evaluated. We also examined the effect of osajin and pomiferin on cardiac function: left ventricular end-diastolic pressure, left ventricular pressure, and peak positive dP/dt. Our results demonstrate that the flavonoids osajin and pomiferin attenuate the myocardial dysfunction provoked by ischemia-reperfusion. This was confirmed by an increase in both the antioxidant enzyme values and the total antioxidant activity. The cardioprotection provided by osajin and pomiferin treatment results from the suppression of oxidative stress and correlates with the improved ventricular function.

Keywords: Maclura pomifera; flavonoids osajin and pomiferin; heart ischemia-reperfusion; free oxygen radicals

Received: January 16, 2006; Accepted: February 27, 2006; Published: April 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nečas J, Bartošíková L, Florian T, Klusáková J, Suchý V, Naggar EMB, et al.. Protective Effects of the Flavonoids Osajin and Pomiferin on Heart Ischemia - Reperfusion. Čes. slov. farm. 2006;55(4):168-174.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lee, S. J., Wood, A. R., Maier, C. G. A. et al.: Phytochemistry, 1998; 49, 2573-2577. Go to original source...
    2. Havsteen, B. H.: Pharmacol. Terapeut., 2002; 96, 67-202. Go to original source... Go to PubMed...
    3. Kollár, P., Kotolová, H.: Čes. slov. Farm., 2003; 52, 272-281.
    4. Rao, Y. K., Fang, S. H., Tzeng, Y. M.: J. Ethnopharmacol., 2005; 100, 249-253. Go to original source... Go to PubMed...
    5. Kandaswami, C., Perkins, E., Soloniuk, D.S. et al.: Cancer Lett., 1991; 56, 147-152. Go to original source... Go to PubMed...
    6. Nishino, H., Tokuda, H., Satomi, Y. et al.: Biofactors, 2004; 22, 57-61. Go to original source... Go to PubMed...
    7. Scambia, G. Ranelletti, F. O., Panici, P. B. et al.: Gynecol. Oncol., 1992; 45, 13-19. Go to original source... Go to PubMed...
    8. Štípek, S. et al.: Antioxidanty a volné radikály ve zdraví a nemoci. 1. vyd. Praha, Grada Publishing, 2000, s. 117-137.
    9. O'Leary, K. A., de Pascual-Tereasa, S., Needs, P. W. et al.: Mutat. Res-Fund. Mol. M., 2004; 551, 245-254. Go to original source... Go to PubMed...
    10. Seaver, B., Smith, J. R.: J. Herb. Pharmacother., 2004; 4, 11. Go to original source...
    11. Selvam, C., Jachak, S. M., Bhutani, K. K.: Phytother. Res., 2004; 8, 582-584. Go to original source... Go to PubMed...
    12. Bayer, J., Gomer, A., Demir, Y. et al.: Clin. Immunol., 2004; 110, 100-108. Go to original source... Go to PubMed...
    13. Zhong, Z., Connor, H. D., Froh, M. et al.: Free Radical. Bio. Med., 2004; 36, 1248-1258. Go to original source... Go to PubMed...
    14. Valachovičová, T., Slivová, V., Sliva, D.: Mini. Rev. Med. Chem., 2004; 4, 881-887. Go to original source... Go to PubMed...
    15. Maxwell, S. R. J., Lip, G. Y. H.: Int. J. Cardiol., 1997; 58, 95-117. Go to original source... Go to PubMed...
    16. Urquiaga, I., Leighton, F.: Biol. Res., 2000; 33, 55-64. Go to original source... Go to PubMed...
    17. Aherne, S. A., O'Brien, N. M.: Nutrition, 2002; 18, 75-81. Go to original source... Go to PubMed...
    18. Vetchý, D., Rabišková, M.: Int. J. Pharm., 2002; 242,: 353-356. Go to original source... Go to PubMed...
    19. Kozlovski, V. I., Vdovichenko, V. P., Chlopicki, S. et al.: Pol. J. Pharmacol., 2004; 56, 767-774.
    20. Buege, J. A., Aust, S. D.: Method. Enzymol., 1978; 52, 302-309. Go to original source... Go to PubMed...
    21. Flohé, L., Gunzler, W. A.: Method. Enzymol., 1984; 105, 114-121. Go to original source... Go to PubMed...
    22. Spitz, D. R., Oberley, L. W.: Anal. Biochem., 1989; 179, 8-18. Go to original source... Go to PubMed...
    23. Štejfa, M. et al.: Kardiologie, 2. vyd. Praha, Grada Publishing, 1998, s. 57-64.
    24. Kaneko, M. Y., Matsumoto, H., Hayashi, A. et al.: Mol. Cell. Biochem., 1994; 139, 91-100. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.